Codexis, Inc. (CDXS) |
| 2.64 0.04 (1.54%) 05-27 16:00 |
| Open: | 2.6 |
| High: | 2.745 |
| Low: | 2.59 |
| Volume: | 588,349 |
| Market Cap: | 240(M) |
| PE Ratio: | -7.54 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 2.98 |
| Resistance 1: | 2.74 |
| Pivot price: | 2.58 |
| Support 1: | 2.35 |
| Support 2: | 1.96 |
| 52w High: | 3.87 |
| 52w Low: | 0.96 |
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
| EPS | -0.350 |
| Book Value | 0.560 |
| PEG Ratio | 13.53 |
| Gross Profit | 0.205 |
| Profit Margin (%) | -40.96 |
| Operating Margin (%) | -52.75 |
| Return on Assets (ttm) | -12.5 |
| Return on Equity (ttm) | -68.9 |
Mon, 11 May 2026
Earnings Release: Here's Why Analysts Cut Their Codexis, Inc. (NASDAQ:CDXS) Price Target To US$6.58 - Yahoo Finance
Mon, 11 May 2026
US$6.58: That's What Analysts Think Codexis, Inc. (NASDAQ:CDXS) Is Worth After Its Latest Results - simplywall.st
Thu, 07 May 2026
Codexis: Q1 Earnings Snapshot - KTVB
Thu, 07 May 2026
Codexis says it has cash through 2027 as siRNA plans advance - Stock Titan
Thu, 07 May 2026
Revenue surges as Codexis (CDXS) narrows quarterly loss and manages debt load - Stock Titan
Thu, 07 May 2026
Codexis (NASDAQ: CDXS) Q1 2026 revenue hits $15.2M as net loss shrinks - Stock Titan
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |